Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
4.750
-0.360 (-7.05%)
Oct 10, 2024, 4:00 PM EDT - Market closed

Company Description

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland.

The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.

It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.

It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics.

Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Molecular Partners AG
Molecular Partners AG logo
Country Switzerland
Founded 2004
IPO Date Jun 16, 2021
Industry Biotechnology
Sector Healthcare
Employees 168
CEO Patrick Amstutz

Contact Details

Address:
Wagistrasse 14
Schlieren, 8952
Switzerland
Phone 41 44 755 77 00
Website molecularpartners.com

Stock Details

Ticker Symbol MOLN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency CHF
IPO Price $21.25
CIK Code 0001745114
CUSIP Number 60853G106
ISIN Number US60853G1067
SIC Code 2836

Key Executives

Name Position
Dr. Patrick Amstutz Ph.D. Co-Founder, Chief Executive Officer, Member of Management Board and Director
Dr. Michael Tobias Stumpp Ph.D. Co-Founder, Executive Vice President of Projects and Member of Management Board
Robert Hendriks Senior Vice President of Finance
Alexander Zurcher Chief Operating Officer and Member of Management Board
Renate Gloggner Executive Vice President of People and Community and Member of Management Board
Daniel Steiner Ph.D. Senior Vice President of Research and Technology
Seth D. Lewis Senior Vice President of Investor Relations, Communications and Strategy
Michael Pitzner General Counsel, Compliance Officer, Senior Vice President Legal and Business Development
Dr. Pamela A. Trail Ph.D. Strategic Consultant
Anne Goubier D.V.M., Ph.D. Senior Vice President of Research and Early Development

Latest SEC Filings

Date Type Title
Aug 26, 2024 6-K Report of foreign issuer
Jun 26, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jun 14, 2024 6-K Report of foreign issuer
Jun 11, 2024 6-K Report of foreign issuer
Jun 3, 2024 6-K Report of foreign issuer
May 17, 2024 6-K/A Filing
May 16, 2024 6-K Report of foreign issuer
Mar 26, 2024 6-K Report of foreign issuer
Mar 14, 2024 20-F Annual and transition report of foreign private issuers
Jan 8, 2024 6-K Report of foreign issuer